



VAL-083

Protocol: DLM-10-001

ASCO Update

June 1, 2015

Forward-Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC and the British Columbia Securities Commission, including our current reports on Form 8-K's, Form 10-Q's and most recent Form 10-K. We do not undertake to update these forward-looking statements made by us.

Rights for Purchasers in Ontario


Securities legislation in Ontario provides certain Ontario purchasers (other than (a) a "Canadian financial institution" or a "Schedule III bank" (each as defined in National Instrument 45-106 – Prospectus and Registration Exemptions), (b) the Business Development Bank of Canada or (c) a subsidiary of any person referred to in (a) or (b) above, if the person owns all the voting securities of the subsidiary, except the voting securities required by law to be owned by the directors of that subsidiary) with a statutory right of action for damages or rescission against an issuer where an offering memorandum, such as this document, contains a "misrepresentation" (as defined in the Securities Act (Ontario)) without regard to whether the purchaser relied on the misrepresentation. The right of action for damages is exercisable not later than the earlier of 180 days from the date the purchaser first had knowledge of the facts giving rise to the cause of action and three years from the date on which payment is made for the securities. The right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to exercise the right of action for rescission, the purchaser will have no right of action for damages against the issuer. In no case will the amount recoverable in any action exceed the price at which the securities were offered to the purchaser and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, the issuer will have no liability. In the case of an action for damages, the issuer will not be liable for all or any portion of the damages that are proven to not represent the depreciation in value of the securities as a result of the misrepresentation relied upon. These rights are in addition to, and without derogation from, any other rights or remedies available at law to an Ontario purchaser. The foregoing is a summary of the rights available to an Ontario purchaser. Ontario purchasers should refer to the complete text of the relevant statutory provisions.

Participants

- **Jeffrey Bacha, BSc MBA**
 - DelMar coFounder, President & Chief Executive Officer
- **Dennis Brown, PhD**
 - DelMar coFounder, Chief Scientific Officer
- **Richard Schwartz, MD**
 - DelMar Chief Medical Officer
- **Kent Shih, MD**
 - Clinical Investigator Sarah Cannon Cancer Research Institute, Nashville TN

VAL-083: First Product Candidate

- Assessed in 42 NCI sponsored Phase 1 and Phase 2 clinical trials
 - Clinically active in multiple cancers including *lung, brain, blood, and cervical*
 - “First-in-class” chemistry
 - Novel alkylating agent
- Unique Anti-cancer Mechanism
 - Inter-strand DNA cross link @ N7 position of guanine
- Pharmacokinetics/Pharmacodynamics
 - Selective for tumor vs. healthy tissue
 - Rapidly crosses blood brain barrier
- Preliminary safety profile established by NCI
 - Dose limiting toxicity: Myelosuppression



4

Speaker Notes – J. Bacha: Review and background of VAL-083 program

VAL-083 is a small molecule chemotherapy, which is structurally and mechanistically unique in comparison to other chemotherapies, including those used in the treatment of GBM.

The active moieties are the small “triangles” depicted in the structural diagram. These epoxide groups have an affinity for the N7 position of guanine. In areas where there is a high concentration of guanine on DNA – such as CpG islands found in the promotor region of many genes, VAL-083 is believed to form cross-links at the N7 position of guanine, leading to double-strand DNA breaks and cancer cell death via apoptosis.


The drug was assessed in more than 40 Phase 1 & Phase 2 NCI-sponsored clinical trials, therefore we have a strong understanding of the mechanism, safety profile and pharmacokinetics – and evidence of historical clinical activity in a range of tumor types, including GBM from the literature.

These initial data form the starting-point for our enthusiasm around VAL-083 and the basis for our clinical development program.

Glioblastoma Multiforme

First Target Market for VAL-083

- Glioblastoma Multiforme (GBM):
The most common and aggressive form of brain cancer
- Large market opportunity:
>\$1 billion annual sales^(a)
- Significant unmet need:
Affects approx. 15,000 adults each year in United States^(b)
Median survival without treatment = 4 ½ months^(c)
Approximately half of patients' tumors fail all other treatments^(c)
5 year survival <3%^(c)



^(a)Evaluate Pharma reports

^(b)Ostrom QT, Gittleman H, Liao P, et al. CBRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. *Neuro Oncol*. 2014

^(c)Johnson, Derek R.; O'Neill, Brian Patrick (2011). "Glioblastoma survival in the United States before and during the temozolomide era". *Journal of Neuro-Oncology* **107** (2): 359-64

Speaker Notes – J. Bacha: Review and background of VAL-083 program

Glioblastoma Multiforme (GBM) is the most common and aggressive form of brain cancer. It is what Ted Kennedy and, more recently, Beau Biden, died from.

This type of cancer affects approximately 15K patients per year in USA – a rare cancer; however, prominent in media coverage due to striking people in the prime of life and the lack of available treatments.

Average life expectancy beyond diagnosis is still well under 2 years – even with the best care.

Surgery is the first step in treatment; however, because this is the brain, the surgeon cannot remove a wide margin of healthy tissue around the tumor to ensure getting all of the cancer – recurrence following surgery is nearly certain.

Standard front-line therapy is chemotherapy with Temodar® + radiation; however, most patients fail this regimen.

We know why they fail: MGMT is a repair mechanism that is responsible for resistance to Temodar.

There is no therapy that has been shown to impact survival for patients failing Temodar. Avastin is approved as second-line therapy in USA but has not been shown to improve survival.

We believe VAL-083 – based on its unique mechanism – has an opportunity to treat these refractory patients, which is a significant (huge) unmet medical need.


VAL-083




Active Independent of MGMT Resistance Mechanism

- VAL-083 is active independent of MGMT chemo-resistance mechanism *in vitro*^(a)
- Measurement of MGMT provides a validated biomarker for patient selection in future clinical trials

U251 cell line
Adult GBM
MGMT negative, TMZ sensitive



T98G
Adult GBM
MGMT positive, TMZ resistant



^(a) Hu et al; AACR 2012

11

Speaker Notes – J. Bacha: Review and background of VAL-083 program

These data were originally presented at AACR in 2012 and are some of the evidence we have developed to show that VAL-083 is active against GBM tumors that are resistant to Temodar.

The top pane shows a tumor that is a LOW expresser of MGMT.

- Both Temodar (blue) and VAL-083 (pink) show a dose response as expected

The bottom pane shows a tumor that is a HIGH expresser of MGMT

- The blue line is flat – Temodar has no activity – even at 100µM, which is 10x the clinically achievable dose
- VAL-083 looks the same in both settings. The IC50 is ~2.5µM in both settings. Thus VAL-083's cancer killing activity is INDEPENDENT of MGMT

These data - combined with historical clinical activity from the literature - are what drives excitement for doctors because it demonstrates that VAL-083 has a potential to treat GBM patients who fail or whose tumors are unlikely to respond to today's standard of care.

There is no viable treatment for these patients today. We believe VAL-083 offers a potential viable treatment option.

Protocol: DLM-10-001

VAL-083 Pharmacokinetic &
Safety Data Overview

7

J. Bacha – turn over to R. Schwartz for discussion of ASCO clinical data

Pharmacokinetic and Safety Data Summary

- DLM-10-001 dosing regimen of VAL-083 achieves doses higher than prior NCI GBM dosing regimen
- PK is predictable and linear at doses up to 40mg/m² (further analysis of 50mg/m² dose ongoing)
- No treatment-related SAEs were reported at doses up to 40 mg/m² daily x 3 every 21 days; the majority of reported AEs mild to moderate up to this dose.
- DLT was observed in two of six (33%) of patients at 50 mg/m² daily x 3 every 21 days, indicating that 50 mg/m² daily x 3 every 21 days is above the MTD.
- DLTs were defined by thrombocytopenia (low platelet counts), with nadir occurring at approximately day 21.
 - Grade 4 thrombocytopenia (Subject 0034)
 - Grade 3 thrombocytopenia with rectal bleeding, hospitalized for platelet transfusion – predisposing condition, hemorrhoids (Subject 0037)
 - Other than Subject 0037, thrombocytopenia resolved rapidly and spontaneously without concomitant treatment
- Additional myelosuppression was observed in the 50/mg² cohort; however, none of these was considered to be a DLT.

8

R. Schwartz speaking notes – ASC PK and Safety Data summary

The data in the upcoming slides are an overview of what we presented at ASCO today.

Refer to slide for observations.

Key points –

- Safely delivering doses higher than NCI clinical trials;
- Dose limiting toxicity is thrombocytopenia as expected based on published literature.

VAL-083 Optimized Dosing Regimen Comparison to Historical NCI Regimen

| DOSE & STUDY | Single Dose (mg/m ²) | Acute Regimen (single cycle: mg/m ²) | Comparative Dose (total mg/m ² @ 35 days) | Dose Intensity (mg/m ² / week) | Status |
|--|----------------------------------|--|--|---|--|
| NCI GBM (Eagan) daily x 5 q 5wks (cycle = 35 days) | 25 | X 5 d = 125 | 125 | 25 | Historical Regimen MYELOSUPPRESSION REPORTED |
| DelMar VAL-083 daily x 3 q 3wks (cycle = 21 days) | 30 | 90 | 180 | 30 | No DLT |
| | 40 | X 3 d = 120 | 240 | 40 | No DLT |
| | 50 | 150 | 300 | 50 | DLT |

9

R. Schwartz speaking notes – ASC PK and Safety Data summary

The table on slide 9 compares the historical NCI dosing regimen to DelMar’s optimized dosing regimen.

NCI: 25mg/m² for 5 consecutive days in a 35 day cycle.

Delmar: 3 consecutive days in a 35 day cycle.

We safely delivered 40mg/m², which represents a significant increase in single dose, dose intensity (25 vs. 40 mg/m² per week) and overall exposure compared to NCI’s dosing cycle (125 vs. 240 mg/m² over 35 days).

Notably, we did observe evidence of dose limiting toxicity at the 50mg/m² dose suggesting this dose is ABOVE the maximum tolerated dose.

VAL-083 Pharmacokinetics

Pharmacokinetic analyses show dose-dependent generally linear systemic exposure with a short plasma terminal half-life of about 1 hour; C_{max} in cohort 7 (40 mg/m²) was 1130 ng/mL (7.7 μM). *In vitro* studies indicate μM concentrations of VAL-083 are effective against various glioma cell lines.

| Cohort | Dose mg/m ² | T _{max} h | C _{max} ng/mL | C _{max} (uM) | AUC ng [*] h/mL | t-1/2* h |
|--------|------------------------|--------------------|------------------------|-----------------------|--------------------------|----------|
| 1 | 1.5 | 0.25 | 16.5 | 0.11 | 18.9 | 2.02 |
| 2 | 3 | 0.25 | 46.4 | 0.32 | 48.5 | 0.83 |
| 3 | 5 | 0.25 | 80.5 | 0.55 | 108.0 | 1.27 |
| 4 | 10 | 0.25 | 172.0 | 1.18 | 191.7 | 1.19 |
| 5 | 20 | 0.25 | 265.5 | 1.82 | 249.9 | 1.22 |
| 6 | 30 | 0.25 | 458 | 3.14 | 704.7 | 1.06 |
| 7 | 40 | 0** & 0.25 | 1130** & 781.5 | 7.7** & 5.4 | 997.9 | 0.90 |

*Terminal half-life, lambda z. All values are mean of 2-6 patients, except ** which is for one patient (#28).

**For patient #28 PK samples were collected immediately after start of infusion, C_{max} was the 1st sample collected soon after start of infusion; for all other patients PK sampling started after the end of the 1 h infusion.

10

R. Schwartz speaking notes – ASC PK and Safety Data summary

The table on slide 10 summarizes the pharmacokinetic observations that were presented today at ASCO

The time to reach peak concentration in the plasma is short – as expected with intravenous administration.


- Note – one patient in cohort 7 (40mg/m² dose) had C_{max} measured immediately after infusion, which accounts for the higher observed C_{max} for one patient

AUC appears linear – this is presented graphically in a later slide

Half life is 1 – 2 hours in plasma, which is consistent with published literature for VAL-083.

Notably, the half-life in the CSF is reported to be more than 20 hours. Since VAL-083 readily crosses the blood brain barrier, we anticipate good accumulation in the CNS and tumor.

PK by dose cohort & published literature (thru dose cohort 7)



PK profile from the literature (Eagan et al 1982) is included to compare current trial data with historical data.

11

R. Schwartz speaking notes – ASC PK and Safety Data summary

This slide depicts plasma concentration as a function of time.


As noted, T_{max} is shortly after infusion with half-life of 1-2 hours.

We observe a nice dose-dependent increase in exposure.

Notably, we can compare this to the expected exposure from the literature and can demonstrate that what we're seeing in our study is consistent with the expected plasma exposure from prior NCI-sponsored research.

NOTE – Eagan study from published literature at 25mg/m² are represented by the orange values – you can see that they fall neatly between our observed 20mg/m² and 30mg/m² dose – as expected.

Dose-AUC Relationship (thru dose cohort 7)



12

R. Schwartz speaking notes – ASC PK and Safety Data summary

Slide 12 a graphical representation of exposure vs. dose.

As previously noted, our data demonstrate that plasma exposure – as measured by area under the curve (AUC) – is linear and predictable up to 40mg/m²

(analysis of 50mg/m² dose PK ongoing).

At 40mg/m², Estimated Tumor Concentration of VAL-083 in Human Brain Exceeds *in vitro* IC₅₀

| Dose and Dosing Day of Each Cycle | Plasma Cmax (µg/mL) ¹ | Estimated Maximum Tumor Concentration in Brain ^{2,3} | | IC ₅₀ in GBM Cell Lines |
|-----------------------------------|----------------------------------|---|------|------------------------------------|
| | | (µg/g tissue) | µM* | µM |
| 40mg/m ² Day-1 | 0.781 | 0.344 | 2.36 | 2.5-5.0 |
| 40mg/m ² Day-2 | 0.781 | 0.503 | 3.45 | 2.5-5.0 |
| 40mg/m ² Day-3 | 0.781 | 0.563 | 3.86 | 2.5-5.0 |

1. From study DLM-10-001, cohort #7; PK was conducted only on Day 1, given the short t-1/2 of ~1h Cmax is assumed to be same for Day 2 & 3.
 2. Percent of plasma drug concentration in brain tumor = 44%, Eckhardt, 1977
 3. Half-life of drug in human brain tumor tissue = 20h, Eckhardt, 1977
- *Volume of 1 g tissue assumed to be 1 mL

13

R. Schwartz speaking notes – ASC PK and Safety Data summary

Slide 13 is important.

KEY MESSAGE:

What these data suggest is that at the 40mg/m² dose, we're achieving TUMOR TISSUE concentrations known to be active against multiple GBM cell lines in the laboratory.

Brief explanation of the data & assumptions:

- We have observed plasma Cmax of 0.781 mg/m² based on a signal infusion.
- The half life in CSF is ~20 hours, so we can expect CSF accumulation with successive daily dosing since VAL-083 readily crosses the blood brain barrier.
- NCI has published previous data showing brain-tumor tissue concentrations following intravenous administration of VAL-083 – we can extrapolate these data to calculate the concentration of VAL-083 that we're achieving at our 40mg/m² dose by day 3.
- Based on this – we anticipate that we're achieving concentrations above the IC50 required for GBM cell kill at the 40mg dose.

This is consistent with the clinical activity data that we will discuss later in the presentation.

DLM-01-001 Summary of Hematologic Toxicity Data

| Hematologic Toxicity and CTCAE Grade | | Cohort 1 - 5 ≤ 20mg/m ² | Cohort 6 30mg/m ² | Cohort 7 40mg/m ² | Cohort 8 50mg/m ² |
|--------------------------------------|----|---------------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Anemia (Hct; Hg) | G1 | - | - | 1/3 (33.3%) | 5/6 (83.3%) |
| | G2 | - | - | - | - |
| | G3 | - | - | - | - |
| | G4 | - | - | - | - |
| Leukopenia (WBC) | G1 | - | 1/3 (33.3%) | 1/3 (33.3%) | 3/6 (50.0%) |
| | G2 | - | - | - | 2/6 (33.3%) |
| | G3 | - | - | - | 2/6 (33.3%) |
| | G4 | - | - | - | - |
| Neutropenia (neutrophils) | G1 | - | - | 1/3 (33.3%) | 2/6 (33.3%) |
| | G2 | - | - | - | - |
| | G3 | - | - | - | 1/6 (16.6%) |
| | G4 | - | - | - | 1/6 (16.6%) |
| Thrombocytopenia (platelets) | G1 | - | 2/3 (66.6%) | 2/3 (66.6%) | 1/6 (16.6%) |
| | G2 | - | - | - | - |
| | G3 | - | - | - | 3/6 (50.0%)* |
| | G4 | - | - | - | 1/6 (16.6%)* |

*DLT observed in 2 of 6 (33.3%) patients in cohort 8 as defined by G4 thrombocytopenia in 1 of 6 patients (16.6%) and Grade 3 thrombocytopenia with hemorrhage in 1 of 6 patients (16.6%)

14

R. Schwartz speaking notes – ASC PK and Safety Data summary


Moving on to safety observations with slide 14

We know from the literature that we expected myelosuppression – namely thrombocytopenia to be the dose limiting toxicity. We reported at AACR that we had observed the first DLT at the 50mg/m² cohort.

Myelosuppressive DLT is expected for any alkylating agent. Fortunately, VAL-083 does not have a history of any other significant toxicity. There's no evidence of cumulative organ damage or severe GI tox in the literature – so as far as chemotherapy goes, it is reasonably well tolerated.

- VAL-083 exhibits a reasonable safety profile at doses below 50mg/m² for our dosing regimen of 3 daily doses every 21 days.
- No drug-related SAEs were reported at doses below 50mg/m² and any observed non-hematologic toxicity was minor.
- In the 30mg/m² and 40mg/m² dose we noted some evidence of mild myelosuppression, which became more frequent at the 40mg/m² dose.
- At the 50mg/m² dose we noted consistent higher-grade myelosuppression, including two DLTs related to thrombocytopenia (low platelets)
 - One patient was grade-4
 - One patient was grade-3 with bleeding related to hemorrhoids; a Grade 3 + bleeding

is considered a DLT according to the protocol



R. Schwartz speaking notes – ASC PK and Safety Data summary

Side 15 depicts the observed platelet counts in the 50mg/m² cohort

KEY MESSAGE: 50mg/m² is above MTD; platelet counts recover rapidly and spontaneously

As you can see, the platelet counts in patients receiving 50mg/m² of VAL-083 were severely impacted with grade 3 and grade 4 thrombocytopenia.

Nadir occurs somewhere around day 21 and the platelet counts recover rapidly from there

Notably, some of the grade 3 thrombocytopenia were close to grade 4 – 27,000 and 28,000 in two separate patients. Based on the fact that we have a “blind spot” in the data since no data were collected between day 14 and day 21, we can look at the slope of the data before and after day 21 and surmise that the NADIR may be before Day 21, suggesting that those patients may actually have had platelet counts below 25,000, which would be grade 4 thrombocytopenia.

Patients with “deep” grade 3 thrombocytopenia also experienced treatment delays, which defeats the purpose of our dosing regimen.

Based on the aggregate of these observations – including two DLTs -- it was determined that 50mg/m² is above the MTD, so we’ve determined to move forward with a 40mg/m² dose into the 14 patient Phase 2 expansion portion of our trial.

We are also exploring an interim 45mg/m² dose – we’ll discuss this later in the presentation.

Protocol: DLM-10-001

Overview of Prior Treatments of GBM
Patients treated with VAL-083

16

Schwartz speaking notes – Prior treatments

Now we'd like to discuss the prior treatments of patients in our trial

DLM-10-001 Treatment History

- True “salvage” population
- Prior treatment of patients enrolled in DLM-10-001 was highly varied
- Protocol specifies GBM after failure of TMZ and BEV unless one or both are contra-indicated.
- Many patients received extensive prior treatment beyond including multiple prior courses of TMZ, BEV, investigational agents and combination therapy.

| Total CRFs Reviewed | 26 | | Multiple COURSES of Treatment following PD | |
|---|----|------|--|----|
| Prior Therapy & # CRFs Reporting | | | 2x | 3x |
| <i>Prior Therapies Per Protocol</i> | | | | |
| Temozolomide | 26 | 100% | 6 | 1 |
| Bevacizumab | 24 | 92% | 7 | 1 |
| OTHER | 20 | 77% | | |
| <i>OTHER PRIOR THERAPIES REPORTED (ranked by prevalence of use)</i> | | | | |
| Irinotecan/Camptosar/CPT-11 | 6 | 23% | - | - |
| BKM-120 | 3 | 12% | - | - |
| Carboplatin | 3 | 12% | - | - |
| CCNU | 3 | 12% | - | - |
| CC-122 pleotropic pathway modifier | 2 | 8% | - | - |
| Gliadel Wafer | 2 | 8% | - | - |
| LY2517299 - biologic | 2 | 8% | - | - |
| Medi-575 | 2 | 8% | - | - |
| Rindopepimut | 2 | 8% | - | - |
| Autologous HSP Vaccine | 1 | 4% | - | - |
| BCNU | 1 | 4% | - | - |
| Etoposide | 1 | 4% | - | - |
| Gleevec | 1 | 4% | - | - |
| GM-CSF | 1 | 4% | - | - |
| Ornartuzimab | 1 | 4% | - | - |
| Vorinostat | 1 | 4% | - | - |

R. Schwartz speaking notes – Prior treatments

Our protocol requires patients to have failed both temozolomide and bevacizumab unless one or both are contra-indicated.

All patients failed Temodar and most also failed Avastin.

What we didn’t necessarily anticipate was the number of prior courses of treatment that some patients had received and the fact that a over three quarters of the patients enrolled had also failed a prior salvage or experimental therapy prior to enrollment.

These patients are truly a salvage – or even a “salvage salvage” – population and would be expected to have a very poor prognosis.

Importantly, we achieved a good safety profile following a range of prior therapies, including vaccines, immunotherapies and aggressive chemotherapy regimens.

Protocol: DLM-10-001

Other Clinical Observations

18

R. Schwartz speaking notes – Prior treatments

No lets move on to other observations

Other Observations

- MGMT expression has been characterized only in 5 patients; however, all patients in this small sample size were “unmethylated”

| <u>MGMT Expression DLM-10-001 Subjects</u> | | |
|--|----------|-------------|
| unknown | | 25 |
| Known | | 5 |
| <hr style="width: 50%; margin: 0 auto;"/> | | |
| <i>unmethylated; high expression</i> | <i>5</i> | <i>100%</i> |
| <i>methylated; low expression</i> | <i>0</i> | <i>0%</i> |

- No patients were re-resected prior to enrollment and therefore had a growing GBM at the time of treatment
- Patients were withdrawn at any sign of progression.
 - To continue stable disease or regression must be established at the first post-treatment MRI
- Near-term progression was anticipated and observed
 - Only six GBM patients received more than two cycles of treatment

| | | | |
|-------------------------|---|-----------|------------|
| Median Treatment | <i>Patients receiving 1 cycle:</i> | <i>7</i> | <i>24%</i> |
| Cycles VAL-083: | <i>Patients receiving 2 cycles:</i> | <i>16</i> | <i>55%</i> |
| 2 | <i>Patients receiving >2 cycles:</i> | <i>6</i> | <i>21%</i> |

19

R. Schwartz speaking notes – Other observations

Slide 19 summarizes what we’ve seen with respect to MGMT and other observations.

We have only characterized MGMT expression in 5 patients; however, all of them were “unmethylated”, which is correlated with high MGMT expression and poor patient outcomes. This is a small sample size, but 100% is an interesting observation.

None of the patients were re-resected in our clinical trial. Since they’d progressed following prior therapy, they had a growing GBM at the time of enrollment.

Thus, we had to expect near-term progression during the dose escalation portion of our clinical trial. In accordance with the protocol, patients were taken off study at any sign of progression, and, as a consequence, most patients only received one or two cycles of therapy.

Median number of cycles = **2** with only six patients receiving more than two cycles of therapy.

With expected near term progression, we also asked the question whether limited treatment could impact survival by slowing tumor growth.

Summary of DLM-10-001 PFS and Survival Data May 29, 2015

| Cohort | Number of GBM patients | VAL-083 Cohort mg/m ² | Median PFS after start of BEV (mo) | Median PFS after start of VAL-083(mo) | Median # Cycles of VAL-083 | Median survival after start of VAL-083 (mo) |
|--------|------------------------|----------------------------------|------------------------------------|---------------------------------------|----------------------------|---|
| all | 29 | All | 5.9 | 1.2 | 2.0 | 4.6 |
| 1 - 3 | 9 | <10 | 8.8 | 1.2 | 2.0 | 4.4 |
| 1 - 5 | 16 | <30 | 6.0 | 1.2 | 2.0 | 5.6 |
| 1 - 7 | 19 | <40 | 7.0 | 1.2 | 2.0 | 5.7 |
| 6 | 3 | 30 | 9.0 | 1.3 | 2.0 | 9.2 |
| 7 | 3 | 40 | 4.2 | 1.4 | 2.0 | 8.8 |
| 6+7 | 6 | 30 and 40 | 6.6 | 1.4 | 2.0 | 9.0 |
| 8 | 6 | 50 | 3.6 | 1.4 | 1.0 | 1.7*(na) |

** Three of 7 patients in Cohort #8(including current median) are still alive, two of whom have only recently begun treatment, thus explaining the short median survival in this cohort.*

R. Schwartz speaking notes – Other observations

What we did see – as depicted on slide 20, is some evidence that we may be impacting patient survival at higher doses. - perhaps by slowed tumor growth.

What you can see here is that in increasing cohorts, the median PFS on Avastin (BEV) was consistent – this suggests that the prognosis of patients across dose cohorts was similar. We’re not seeing “better” patients at the higher dose cohorts.

Median PFS on VAL-083 was consistently short around 1.2 – 1.4 months. We expected this, and as a consequence of protocol design, the median number of treatment cycles was two.

Notably, we see a trend toward increased survival as we go to higher doses.

- Across all cohorts the median survival was 4.6 months following initiation of VAL-083
- In patients receiving <10mg/m² the median survival was 4.4 months following initiation of VAL-083
- As we increased dose, the median survival also increased, with patients receiving ≥30mg/m² having a median survival of 9 months following initiation of VAL-083.

With the caveat that this is a small number of subjects, this observation is clinically meaningful and promising in this post-Avastin, post-salvage population. This will be explored further in the Phase 2 expansion cohort.

It is worth noting, that patients in the 50mg/m² cohort haven't enrolled that long ago, so the data aren't meaningful. Notably, 3 of 7 patients in this cohort – including the current median –

are still alive (although the 50mg/m² dose is above MTD and not being considered for further exploration).

DLM-10-001 PFS and Survival Data Interpretations

- Median PFS on VAL-083 following failure of prior therapies is short: 1.2 – 1.4 mo.
 - ❖ *This was expected as patients were not-resected following failure of prior therapy*
- Median survival appears to increase with increasing dose of VAL-083: 9.0 mo at doses ≥ 30 mg/m²
 - ❖ *Is there potential for slowed tumor growth benefiting survival?*
- Dose-response is suggested
 - ❖ *Small sample size considered, this a promising trend*
 - ❖ *14 patient Ph II expansion cohort will provide further data regarding median survival*
- Hypothetical sample size estimates for controlled Phase 2 - 3 clinical trial
 - ❖ Assumptions: 1:1 randomization, $\alpha = 0.05$, power = 80%, accrual = 12 mo., follow-up = 6-12 mo.
 - ❖ Median survival values control vs. VAL-083 therapy:
 - 3.0 vs. 6.0 mo: 34 patients/arm
 - 4.4 vs. 9.0 mo: 33 patients/arm
 - 4.6 vs. 9.0 mo: 38 patients/arm


R. Schwartz speaking notes – Other observations

To summarize (refer to slide)

We can also use these observations to estimate the size of a future registration trial, which as you can see is relatively manageable in terms of the number of patients required. (refer to slide)

Other Observations

- Anecdotal Observation:
 - Sakruti et al (2014): Median OS from start of bevacizumab = 12.2 mos (95%CI, 10.0 14.3)
 - To date, 59% of VAL-083 patients have survived longer than 12.2 months



J. Bacha – Other Observations

Another way we looked at the data was to compare to information about GBM outcomes in the context of Avastin therapy from the published literature.


At ASCO last year, a retrospective study of survival from the START of Avastin therapy was presented. The authors noted that the survival was consistent after first, second, or later recurrence – median survival following the START of Avastin therapy was just over 1 year.

At this point, 59% of patients treated with VAL-083 have survived for longer than predicted following the start of Avastin.

This is anecdotal, but interesting.

Other Observations

- Anecdotal Observation:
 - Iwamoto et al (2009):
 - Median OS for BEV-failed GBM Patients receiving salvage therapy = 5.2 months
 - Median OS for BEV-failed GBM patients receiving supportive care only = 2 months
 - To date, 48% of patients treated with VAL-083 have survived longer than 5.2 months and 75% have survived longer than 2 months



23

J. Bacha – Other Observations

We also looked at predicted survival following FAILURE of Avastin.

Median survival following Avastin FAILURE with hospice care is 2 months. 75% of patients treated with VAL-083 have done better than this.

Median survival following Avastin FAILURE with salvage therapy is 5.2 months. 48% of patients treated with VAL-083 have done better than this, with others tracking toward this milestone.

This is anecdotal, but interesting.

As noted earlier, patients receiving higher doses of VAL-083 had a median survival of 9 months, suggesting a substantial benefit in comparison to salvage therapy.

Other Observations

- *Is there potential for slowed tumor growth benefiting OS?*
- Following initiation of VAL-083 in bevacizumab-failed GBM patients
(*median cycles VAL-083 = 2*)
 - **6 month OS = 41.4%**
 - *Two additional patients from later cohorts are alive, but have not yet reached 6 month OS*
 - **12 month OS = 17.2%**
 - *Four additional patients from later cohorts are alive, but have not yet reached 12 month OS*
 - 10% (3 of 29) patients had a longer time to progression than prior treatment with bevacizumab
 - To date:
 - 59% of patients survived longer than predicted following BEV initiation
 - 75% of patients survived longer than predicted following BEV failure with supportive hospice care
 - 48% of patients survived longer than predicted following BEV failure salvage therapy
 - Preliminary analysis shows increasing dose-dependent median survival supporting a trend toward dose response.

24

J. Bacha – Other Observations

To summarize:

The 6 month and 12 month survival in an Avastin *and salvage* failed population is 41.4% and 17.2% respectively, with a number of patients still alive and tracking toward these survival milestones.

Patients treated with VAL-083 appear to be doing better than predicted in the context of Avastin-related GBM literature.

Patients at the higher dose cohorts had a median survival of 9 months, suggesting a dose response and the potential for meaningful clinical impact for refractory GBM patients with no viable treatment options.

Next Steps

- 14 patient Phase 2 expansion cohort initiated
 - 40mg/m² daily x 3 in a 21 day cycle
 - Additional 3 pt safety cohort @ 45mg/m²
 - Patients will be continued to 45mg/m² if supported by safety data
- Preparation underway for design of registration-directed Phase 2 - 3 clinical trial

25

J. Bacha – Next Steps

Obviously, we find these data to be encouraging and we're excited to be moving forward with the next steps in the development of VAL-083 for refractory GBM.

We have initiated a 14-patient Phase 2 expansion cohort at a 40mg/m² dose – the first patient has already been enrolled.

Based on preliminary evidence of a dose response, our clinical advisors believe exploring an interim 45mg/m² is worthwhile. We have received IRB approval at two sites to enroll a small safety cohort at 45mg/m². If the safety data warrant, we will continue the 14 patient expansion at this higher dose.

Otherwise, our dose for registration-directed Phase 2 - 3 studies will be 40mg/m².

We anticipate reporting initial data from the 14-patient Phase 2 expansion later this year.

We have also initiated activities related to advancing into pivotal registration-directed Phase 2 - 3 trials with VAL-083 in refractory GBM.

QUESTIONS

